https://www.selleckchem.com/pr....oducts/semaglutide.h
42, 95% CI 0.25-0.70, p=0.001, RRR 58%). sCR showed a significant reduction in non-fatal reinfarctions only (RR 0.68, 95% CI 0.54-0.85, p=0.0008, RRR 32%). There was no difference in the safety outcome of contrast-induced nephropathy between groups. iCR of stable STEMI patients is associated with a significant reduction in cardiovascular death and a trend towards reduction in all-cause mortality. These benefits are not seen in sCR. Both strategies are associated with a reduction in non-fatal reinfarctions. iCR of stable STEMI patien
Like
Comment
Share
